|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated levels of preoperative tumor markers (TMs), including carcinoembryonic antigen and carbohydrate antigen 19-9 are risk factors for the survival of patients with pancreatic cancer (PC).
|
31030989 |
2020 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivities of PhoSL-HP, CA19-9 and CEA for PC were 58%, 76% and 42%, respectively.
|
31031206 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate PIVKA-II in comparison to established pancreatic cancer (PC) biomarkers (CA 19-9, carcinoembryonic antigen (CEA) and CA 242) measured in PC patients and in patients with benign pancreatic diseases.
|
31223261 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of analysis of KRAS mutation or immunohistochemistry with MUC1 and carcinoembryonic antigen improves the diagnostic performance of fine needle aspiration cytology for the diagnosis of pancreatic carcinoma.
|
30929285 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and CA-125 in blood are used as markers to determine response of patients with cancer to therapy, but are not used to identify patients with pancreatic cancer.
|
31676359 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The findings of the present study indicated that CA 19-9 levels were associated with higher sensitivity, DOR, and AUC compared with the corresponding levels of CEA with regard to the diagnosis of pancreatic cancer.
|
30584422 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used the BEAMing technology to determine levels of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 in 284 plasma samples of 54 patients with advanced PC receiving gemcitabine-based chemotherapy.
|
30346475 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our previous study, we identified a specific subgroup of patients with pancreatic cancer with a serum signature of carcinoembryonic antigen (CEA)+/cancer antigen (CA)125+/CA19-9 ≥1,000 U/ml.
|
29436617 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fluorescent-guided surgery for sentinel lymph node detection in gastric cancer and carcinoembryonic antigen targeted fluorescent-guided surgery in colorectal and pancreatic cancer.
|
30216455 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Carcinoembryonic antigen (CEA) is a candidate target for cellular immunotherapy of pancreatic cancer.
|
28710313 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Best performance was found for CEA in colorectal cancer (area under the curve=0.84, sensitivity=51.7% at 95% specificity vs. benign), CA19-9 in gallbladder/pancreatic cancer (AUC=0.85, sensitivity=60.6%) and AFP in liver cancer (AUC=0.87, sensitivity=68.4%).
|
28011514 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Another model to discriminate PC from BTC and IPMC yielded AUC = 0.831 (95% CI, 0.650-1.01, <i>p</i> = 0.0020) with higher accuracy compared with tumor markers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), pancreatic cancer-associated antigen (DUPAN2) and s-pancreas-1 antigen (SPAN1).
|
28375170 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) and CA125 had greater sensitivity than other biomarkers in Lewis negative patients with pancreatic cancer [CEA, 63.8%; CA125, 51.1%; CA72-4, 25.5%; CA15-3, 21.3%; CA19-9, 19.1%; CA50, 12.8%; CA242, 10.6%; and alpha-fetoprotein (AFP), 0.0%].
|
28267695 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.
|
28979147 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that miR-25 had significant diagnostic value for the differential diagnosis of PaC in normal controls with an AUC (the area under the ROC curve) of 0.915 (95% CI: 0.893-0.937) that was significantly higher compared with an AUC of 0.725 for serum tumor marker carcinoembryonic antigen (CEA) and an AUC of 0.844 for CA19-9.
|
27639768 |
2016 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer.
|
25409014 |
2014 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The higher expression of CD44v6, integrin-β1, CA199, and CEA are closely related to the progression and metastasis of pancreatic cancer and may play a important role in the curative evaluation of cryosurgery of pancreatic cancer.
|
22382453 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further we compared the sensitivity and specificity of determining galectin-3, carcinoembryonic antigen (CEA) and carbohydrate antigen199 (CA199) for diagnosis of pancreatic carcinoma and assessed the complementary diagnostic value of galectin-3, CEA and CA199 for pancreatic carcinoma.
|
22367363 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the human pancreatic cancer Panc-1 xenograft model in immune deficient nude mice, the CEA promoter-regulated adenovirus AdCEAp-Hsp70 significantly inhibited tumor growth.
|
22261331 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT-PCR for CEA is a sensitive and specific method for the detection of clinically significant peritoneal micrometastases from pancreatic cancer and it might identify a subgroup of patients with otherwise negative findings at staging laparoscopy who might respond better to treatment other than primary surgical resection.
|
19763694 |
2009 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An open-label Phase 1 study of recombinant prime-boost poxviruses targeting CEA and MUC-1 in patients with advanced pancreatic cancer was conducted to determine safety, tolerability and obtain preliminary data on immune response and survival.
|
18039393 |
2007 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No association was found between CEA mRNA and stage in patients with GC or PC.
|
11096345 |
2000 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CEA-mRNA expression was detected in the blood of 21 (52.5%) of 40 patients with biliary-pancreatic cancer.
|
10414697 |
1999 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the therapeutic efficacy of AdCEAtk and GCV administration in human CEA-positive pancreatic cancer in vivo, a subcutaneously implanted tumor-bearing nude mouse model was used.
|
9617353 |
1998 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients.
|
8950323 |
1996 |